Last reviewed · How we verify
NCT06796699
A Phase Ia/Ib Clinical Study of GH56 Capsules in Subjects With MTAP-Deleted Advanced Solid Tumors
Phase 1 trial testing GH56 Capsule in Advanced Solid Tumors With MTAP Gene Deletion in 90 participants. Currently enrolling.
31 December 2027
Quick facts
| Lead sponsor | Suzhou Genhouse Bio Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 90 |
| Start date | 7 March 2025 |
| Primary completion | 31 December 2027 |
| Estimated completion | 29 February 2028 |
| Sites | 4 locations across China |
Drugs / interventions tested
- GH56 Capsule — full drug profile →
Conditions studied
- Advanced Solid Tumors With MTAP Gene Deletion — all drugs for Advanced Solid Tumors With MTAP Gene Deletion →
Sponsor
Suzhou Genhouse Bio Co., Ltd. — full company profile →
Who can join
18 and older, any sex, with Advanced Solid Tumors With MTAP Gene Deletion. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multicenter, single-arm, open-label, dose-escalation, dose-expansion study to evaluate the safety, tolerability, PK/PD, and preliminary anti-tumor activity of GH56 Capsule in subjects with advanced solid tumors who have failed or are intolerant in standard treatment, or have no standard therapy. The clinical trial will be carried out in two parts: phase Ia study (dose escalation study) and phase Ib (dose expansion study).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
<i>MTAP</i> Deletion as a Therapeutic Vulnerability in Cancer: From Molecular Mechanism to Clinical Targeting.
Krawczyk P, Wojas-Krawczyk K. · · 2025 · PMID 41465382 · DOI 10.3390/ijms262411956
Verify or expand the search:
- PubMed search for NCT06796699
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Suzhou Genhouse Bio Co., Ltd. trials
Trials by the same sponsor.
- NCT07446725 — A Study to Evaluate Safety, PK and Efficacy of GH55 in Combination With GH21 in Patients With Solid Tumors · Phase 1, PHASE2 · not yet recruiting
- NCT07318649 — Phase 2 Clinical Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GH21 Capsules Combined Wi · Phase 2 · not yet recruiting
- NCT07260513 — A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GH2616 in Subjects W · Phase 1 · active not recruiting
- NCT06435455 — GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors · Phase 1, PHASE2 · not yet recruiting
- NCT06322095 — A Study of GH21 Combined With Previous Target Therapy or Immunotherapy in Patients With Advanced Solid Tumors · Phase 2 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06796699 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Suzhou Genhouse Bio Co., Ltd.
- Last refreshed: 28 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06796699.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing